Digitek & Bertek Lawsuits - Digitek Recall - Digoxin Tablet

The fact that digoxin is considered as Narrow Therapeutic Index drug can have a lot of bearing on the Digitek & Bertek lawsuits.

Helpful Information On Digitek & Bertek Lawsuits
The following information can prove helpful in Digitex & Bertek lawsuits.

Digitek
Digitek (digoxin tablet) is used for the treatment of certain heart ailments such as congestive heart failure.

Digitek Recall
The United States Food and Drug Administration (FDA) posted an important notice in April 2008 on the recall of the drug Digitek by Actavis Totowa LLC. This is a class I nationwide recall of Digitek (generic name digoxin) for oral use. Mylan Pharmaceuticals Inc. distributes the product, under the label “Bertek” and UDL Laboratories Inc, under the label “UDL”. The reason cited by the drug company for recall is that there was possibility that tablets with double the appropriate thickness may have been commercially released. These tablets may contain twice the amount of active ingredient than is recommended by doctors. Overdose of Digitek poses the risk of causing severe side effects related to digitalis toxicity. This is a critical aspect of Digitek & Bertek lawsuits.

Over Dosage And NTI
FDA has identified some drugs as having a Narrow Therapeutic Index. With NTI drugs, small changes in dosage can cause significant toxic results. Patients taking NTI drugs need constant monitoring by doctors to ensure correct dosage for safe results. Wellmarks drug list, which provides names of drugs, covered under NTI drugs includes Digitek. Wellmarks clearly documents the clinical limitations of Digitek. This information can benefit the outcome of the Digitek & Bertek lawsuits.